JP2022544701A - Peptide having hair growth promoting activity and use thereof - Google Patents

Abstract

Peptide having hair growth promoting activity and use thereof, peptide consisting of amino acid sequence of SEQ ID NO: 1, cosmetic composition for improving hair loss or promoting hair growth containing said peptide, and hair loss preventing use containing said peptide Alternatively, a pharmaceutical composition for treating hair loss is provided.

Description

TECHNICAL FIELD The present invention relates to peptides having hair growth promoting activity and uses thereof.

As the aging society develops, the number of people suffering from hair loss is increasing, and in the past, it was a major problem for middle-aged men, but recently, it is becoming more popular among young people and women to prevent hair loss. Interest in hair care is increasing. On the other hand, hair loss has been recognized as a series of aging conditions, but recently, hair loss is caused by various factors such as genetic factors, stress, westernized eating habits, nutritional imbalance, and changes in social activities. has been shown to progress.

At present, minoxidil (6-Amino-1,2-dihydro-1-hydroxy-2-imino-4-phenoxypyrimidine) (US Patent No. 3, 382,247) and finasteride (US Pat. No. 5,215,894). In the case of minoxidil, it was developed as a vasodilator for the treatment of hypertension in the early 1970s, but while hirsutism was reported as a side effect, it was used as a hair growth stimulant, resulting in enlarged pores and reduced hair diameter. increases, showing the effect of thickening the hair. In the case of finasteride, which was developed as a therapeutic agent for benign prostatic hyperplasia and is currently used as a therapeutic agent for hair loss, it delays the progress of hair loss and exhibits a hair growth effect.

However, in the case of minoxidil, side effects such as weight gain, swelling, dermatitis, and increased heart rate have been reported; in the case of finasteride, continuous dosing is required; in men, sexual dysfunction; In some cases, there are side effects such as birth of malformed babies, and there is still a demand for the development of hair loss therapeutic agents without side effects.

Under such a technical background, multifaceted studies are underway to improve hair loss through mechanisms such as hormonal regulation and metabolic regulation (Korea Patent Publication No. 2002-0005332), but it is still sufficient. It is not the actual situation.

Korean Patent No. 2002-0005332

One aspect provides a peptide consisting of the amino acid sequence of SEQ ID NO:1.

Another aspect provides a cosmetic composition for improving hair loss or promoting hair growth, comprising the peptide.

Yet another aspect provides a pharmaceutical composition for preventing or treating hair loss comprising said peptide.

Other objects and advantages of the present application will become more apparent from the detailed description below, together with the appended claims and drawings. A person skilled in the art in the technical field of the present application or a similar technical field can fully recognize and infer the contents that are not described in this specification, so the explanation thereof is omitted. .

Each description and embodiment disclosed in this application also applies to each other description and embodiment. That is, all combinations of various elements disclosed in this application are within the scope of this application. Also, the specific statements set forth below are not intended to limit the scope of this application.

One aspect provides a peptide consisting of the amino acid sequence of SEQ ID NO:1.

As used herein, the term "peptide" can refer to a linear molecule formed by amino acid residues joined together by peptide bonds. Said peptides are prepared by chemical synthesis methods known in the art, in particular solid-phase synthesis techniques (Merrifield, J. Amer. Chem. Soc. 85: 2149-54 (1963); Stewart, et al.). al., Solid Phase Peptide Synthesis, 2nd. ed., Pierce Chem. Co.: Rockford, 111 (1984)), or by liquid synthesis techniques (US Pat. No. 5,516,891). The present inventors have devoted their efforts to developing a peptide having biologically effective activity, and as a result, have found a peptide consisting of the amino acid sequence of SEQ ID NO:1. Here, the biologically effective activity includes (a) promotion of hair follicle cell activity, (b) promotion of growth of hair follicle cells, (c) suppression of growth promotion and death of hair follicle cells, and (d) DKK. -1 (Dickkopf-related protein 1) or TGF-β1 (transforming growth factor-beta 1) expression suppression properties. Therefore, the peptide is also used for improving hair loss, promoting hair growth, and preventing or treating hair loss.

The peptides exhibit chemical stability, enhanced pharmacological properties (half-life, water absorption, potency, potency, etc.), altered specificity (e.g., broad spectrum of biological activity), reduced antigenicity, Protecting groups are also attached to the N-terminus or C-terminus of the peptides to obtain . In one embodiment, the N-terminus of the peptide is an acetyl group, a fluorenylmethoxycarbonyl group, a formyl group, a palmitoyl group, a myristyl group. ), stearyl group, butoxycarbonyl group (Boc: butoxycarbonyl group), allyloxycarbonyl group (Alloc: allyloxycarbonyl group) and polyethylene glycol (PEG: any one selected from the group consisting of polyethylene glycol) and/or the C-terminus of the peptide is selected from the group consisting of an amino group ( _-NH2 ), a tertiary alkyl group and an azide ( _-NHNH2 ). Any one protecting group is also attached. The peptides also optionally additionally include targeting sequences, tags, labeled residues, purpose-built amino acid sequences to increase half-life or peptide stability. .

The term "stability" as used herein may refer not only to in vivo stability, which protects the peptide from attack by proteolytic enzymes in vivo, but also to storage stability (e.g., shelf stability at room temperature). .

Other aspects are a cosmetic composition containing a peptide containing the amino acid sequence of SEQ ID NO: 1 as an active ingredient, a pharmaceutical composition containing a peptide containing the amino acid sequence of SEQ ID NO: 1 as an active ingredient, and a cosmetic or pharmaceutical composition. Use of a peptide comprising the amino acid sequence of SEQ ID NO: 1 for manufacturing a cosmetic composition, or for use as a cosmetic or pharmaceutical composition.

Another aspect provides a cosmetic composition for preventing hair loss or promoting hair growth comprising said peptide.

Among the terms or elements referred to in the description related to the peptide, the same as those already referred to are as described above.

As used herein, the term "amelioration" may mean any action that at least reduces the severity of a parameter, eg, symptom, associated with alleviation of a condition or treatment.

As used herein, the term "improving hair loss" comprehensively means the process of treating, alleviating, or alleviating the state of hair loss, or the effect thereof. , inhibition of hair follicle cell death, and inhibition of the expression of hair loss-inducing factors such as DKK-1 and TGF-β1.

As used herein, the term "promoting hair growth" means any action that promotes hair growth from a hair follicle, such as hair follicle cell proliferation, hair follicle cell activity, or hair follicle cell activity can mean any action that increases the total amount of hair, such as the effect of promoting the growth of hair.

Conventional functional peptides, despite their effective biological activity, do not enter target tissues or cells effectively due to the size of the peptides themselves, or have short half-lives and disappear in the body in a short period of time. It showed the shortcomings. On the other hand, the cosmetic composition according to one embodiment contains a peptide consisting of 10 amino acids or less as an active ingredient, so that the skin penetration rate of the active ingredient is very good, for example, it can be topically applied to the skin. In this case, it can effectively prevent hair loss and promote hair growth.

According to one example, the peptide showed effects of promoting proliferation of dermal papilla cells, promoting the expression of growth-related factors, promoting the proliferation mechanism, and suppressing the expression of hair loss-related factors. Therefore, the peptide is also used as an active ingredient of a cosmetic composition for improving hair loss or promoting hair growth.

The cosmetic composition may include, but is not limited to, a cosmetically effective amount of the peptide and/or a cosmetically acceptable carrier.

As used herein, the term "cosmetically effective amount" can mean an amount sufficient to achieve hair loss improving efficacy or hair growth promoting efficacy of the cosmetic composition.

The weight ratio of the peptide and the cosmetically acceptable carrier is also, for example, 500:1 to 1:500, for example, the weight ratio is 450:1 to 1:450, 400:1 to 1 : 400, 350:1 to 1:350, 300:1 to 1:300, 250:1 to 1:250, 200:1 to 1:200, 150:1 to 1:150, 100:1 to 1:100 , 80:1 to 1:80, 60:1 to 1:60, 40:1 to 1:40, 20:1 to 1:20, 10:1 to 1:10, 8:1 to 1:8, 6 :1 to 1:6, 4:1 to 1:4, or 2:1 to 1:2, but are not limited thereto.

The cosmetic composition can be manufactured in any dosage form commonly manufactured in the industry, such as solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant, etc. Agent-containing cleansers, oils, powder foundations, emulsion foundations, wax foundations, sprays, etc. are also formulated, but not limited to them. For example, it can be manufactured in the form of soft lotion, nutritional lotion, nutritional cream, massage cream, essence, eye cream, cleansing cream, cleansing foam, cleansing water, pack, spray or powder.

When the dosage form of the cosmetic composition is paste, cream or gel, the carrier component may be animal oil, vegetable oil, wax, paraffin, starch, tracanth, cellulose derivative, polyethylene glycol, silicon, bentonite. , silica, talc or zinc oxide may be used.

When the dosage form of the cosmetic composition is powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder is used as the carrier component. may additionally contain propellants such as chlorofluorohydrocarbons, propane/butane or dimethyl ether.

When the dosage form of the cosmetic composition is a solution or an emulsion, a solvent, a solubilizer or an emulsifying agent is used as the carrier component. Examples include water, ethanol, isopropanol, ethyl carbonate, Ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyl glycol oil, glycerol fatty esters, polyethylene glycol or fatty acid esters of sorbitan may be included.

When the dosage form of the cosmetic composition is a suspension, the carrier components include a liquid diluent such as water, ethanol or propylene glycol, ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and poly Suspending agents such as oxyethylene sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar or tracanth and the like may be employed.

When the dosage form of the cosmetic composition is a surfactant-containing cleansing agent, fatty alcohol sulfates, fatty alcohol ether sulfates, solphosuccinic acid monoesters, isethionates, imidazolinium derivatives, Methyl taurate, sarcosinate, fatty acid amide ether sulfates, alkylamidobetaines, fatty alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters and the like can be utilized.

Ingredients contained in the cosmetic composition include, in addition to peptides and carrier components as active ingredients, ingredients commonly used in cosmetic compositions, such as antioxidants, stabilizers, solubilizers, Common adjuvants such as agents, vitamins, pigments and fragrances may also be included.

Yet another aspect provides a method for improving hair loss or promoting hair growth, which comprises applying a cosmetic composition containing, as an active ingredient, a peptide consisting of the amino acid sequence of SEQ ID NO: 1 to the skin of an individual.

Among the terms or elements referred to in the description of the cosmetic composition, the same as those already referred to are as described above.

As used herein, the terms "apply," "administer," and "apply" are used interchangeably to provide at least partial localization of a composition according to one embodiment to a desired site. or placing a composition according to an embodiment into an individual by route of administration.

Yet another aspect provides a pharmaceutical composition for preventing or treating hair loss, comprising a peptide consisting of the amino acid sequence of SEQ ID NO: 1 as an active ingredient.

Among the terms or elements referred to in the description related to the peptide, the same as those already referred to are as described above.

As used herein, the term "prevention" means any act of suppressing or delaying the onset of a disease by administering the composition.

As used herein, the term "treatment" refers to treating an individual suffering from, or at risk of developing, a disease by ameliorating the individual's condition (e.g., one or more symptoms), slowing disease progression, It means any form of treatment that provides an effect, including delaying the onset of symptoms or slowing the progression of symptoms. Accordingly, the foregoing "treatment" and "prevention" are not intended to imply cure or complete elimination of symptoms.

The "individual" means a subject in need of treatment for a disease, more specifically, a human or a non-human mammal such as a primate, a mouse, a dog, a cat, a horse, or a cow.

"Alopecia", which is a target disease for prevention or treatment with the pharmaceutical composition, means a state in which there is no hair in areas where hair should normally exist, specifically, hair growth on the scalp (thick and black hair). The causes of hair loss are also induced by a variety of dietary and environmental influences, such as, but not limited to, genetic causes, hormonal imbalance, psychological stress, exposure to air pollution, and consumption of processed foods. be. For example, alopecia includes hereditary androgenic alopecia (baldness), alopecia areata, tinea capitis due to fungal infection, telogen effluvium, trichotillomania, and disorders of hair production disorders. It may refer to hair loss due to lupus, folliculitis bald, lichen planus pilaris, hair loss due to burns and trauma.

According to one example, the peptide showed an effect of promoting the proliferation or activity of hair follicle cells and an effect of suppressing the expression of factors related to hair loss. Therefore, the peptide is also utilized as an active ingredient of a pharmaceutical composition for preventing or treating hair loss.

Said pharmaceutical composition also includes, but is not limited to, a pharmaceutically effective amount of said peptide and/or a pharmaceutically acceptable carrier.

The term "pharmaceutically effective amount" as used herein means an amount sufficient to achieve the hair loss preventive or therapeutic efficacy of said pharmaceutical composition.

The weight ratio of said peptide and pharmaceutically acceptable carrier is also, for example, 500:1 to 1:500, for example, said weight ratio is 450:1 to 1:450, 400:1 to 1 : 400, 350:1 to 1:350, 300:1 to 1:300, 250:1 to 1:250, 200:1 to 1:200, 150:1 to 1:150, 100:1 to 1:100 , 80:1 to 1:80, 60:1 to 1:60, 40:1 to 1:40, 20:1 to 1:20, 10:1 to 1:10, 8:1 to 1:8, 6 :1 to 1:6, 4:1 to 1:4, or 2:1 to 1:2, but are not limited thereto.

The pharmaceutically acceptable carriers are those commonly used in formulations, and include lactose, dextrose, sucrose, sorbitol, mannitol, starch, gum acacia, calcium phosphate, alginate, gelatin, calcium silicate, microcrystals. cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, mineral oil and the like. Suitable pharmaceutically acceptable carriers and formulations are described in detail in Remington's Pharmaceutical Sciences (19th ed., 1995).

The pharmaceutical composition may additionally contain lubricants, wetting agents, sweetening agents, flavoring agents, emulsifying agents, suspending agents, preservatives, etc. in addition to the above ingredients, but are not limited thereto. do not have.

The pharmaceutical composition can be administered orally or parenterally, preferably parenterally. In the case of parenteral administration, intramuscular injection, intravenous injection, subcutaneous injection, intraperitoneal injection and topical administration. , transdermal administration, etc., but are not limited thereto.

The dosage of the pharmaceutical composition is 0.0001 to 1,000 μg, 0.001 to 1,000 μg, 0.01 to 1,000 μg, 0.1 to 1,000 μg, or 1.0 to 1,000 μg per day. 1,000 μg, but not limited thereto, formulation method, administration method, patient age/weight/sex, disease state, food and drink, administration time, administration route, excretion rate, and reaction sensitivity It is also prescribed differently depending on factors such as gender.

The pharmaceutical composition utilizes a pharmaceutically acceptable carrier and/or excipient by a method that can be easily carried out by a person skilled in the art to which the present invention belongs. Formulated to be prepared in unit dose form or in multi-dose containers.

Yet another aspect provides a method of preventing or treating hair loss, comprising administering to an individual a therapeutically effective amount of a pharmaceutical composition comprising a peptide consisting of the amino acid sequence of SEQ ID NO: 1 as an active ingredient. .

Terms or elements referred to in the description of the pharmaceutical composition that are the same as those already referred to are as described above.

Yet another aspect provides a food composition for preventing hair loss or promoting hair growth, comprising a peptide consisting of the amino acid sequence of SEQ ID NO: 1 as an active ingredient.

Among the terms or elements referred to in the description related to the peptide, the same as those already referred to are as described above.

The content of the peptide as an active ingredient contained in the food composition is appropriately selected without limitation according to the form of the food, the desired use, etc. For example, it is 0.01 to 15% by weight of the total weight of the food. can be added. Also, for example, the health drink composition may be added at a ratio of 0.02 to 10 g, preferably 0.3 to 1 g, based on 100 ml.

The peptide according to one aspect can be applied to improve, prevent, or treat hair loss by suppressing the expression of a hair loss-related factor (DKK-1 or TGF-β1).

The peptide according to one embodiment can be applied to promote hair growth, hair growth, etc. by promoting proliferation, growth or activity of hair follicle cells.

According to a peptide according to one aspect, therefore, said peptide is also included as an active ingredient for improving hair loss or promoting hair growth in a cosmetic or pharmaceutical composition.

It is the result of confirming the effect of the peptide consisting of the amino acid sequence of SEQ ID NO: 1 to promote the proliferation of hair follicle cells. As a result of confirming that the peptide consisting of the amino acid sequence of SEQ ID NO: 1 induces the phosphorylation of ERK and AKT, which are factors involved in the proliferation of dermal papilla cells, that is, the activation of hair follicle cell proliferation-promoting effects. be. This is the result of confirming that the peptide consisting of the amino acid sequence of SEQ ID NO: 1 increases the movement of β-catenin, which is a factor involved in the proliferation of dermal papilla cells, from the cytoplasm to the nucleus as a hair follicle cell proliferation-promoting effect. This is the result of confirming that the peptide consisting of the amino acid sequence of SEQ ID NO: 1 suppresses the DKK-1 expression pathway by DHT treatment as an effect of suppressing the expression of hair loss-related factors in hair follicle cells. This is the result of confirming that the peptide consisting of the amino acid sequence of SEQ ID NO: 1 suppresses the TGF-β1 expression pathway as an effect of suppressing the expression of hair loss-related factors in hair follicle cells.

Hereinafter, it will be described in more detail through examples. However, the examples are for illustrative purposes only, and the scope of the invention is not limited to the examples.

Example 1 Synthesis of Peptide Using an automatic peptide synthesizer (Milligen 9050, Millipore, USA), a peptide having the amino acid sequence of SEQ ID NO: 1 listed in Table 1 below was synthesized and subjected to C18 reversed phase high performance liquid chromatography. (HPLC) (Waters Associates, USA) was used to separate the synthesized peptides in pure water. The column utilized was an ACQUITY UPLC BEH300 C18 (2.1 mm×100 mm, 1.7 μm, Waters Co., USA).

実施例２：ペプチドの毛嚢細胞増殖または活性促進効果の確認
１．毛乳頭細胞（dermal papilla cell）の増殖促進効果確認
配列番号１のアミノ酸配列からなるペプチドの毛嚢細胞の増殖促進効果を確認する。具体的には、ヒト毛嚢毛乳頭細胞（human hair follicle dermal papilla cells）を、５ｘ１０^３細胞／ウェルの密度で、９６ウェルプレートにシーディングした後、１６時間培養した。無血清培地に替えた後、前記ペプチドを、０．５μＭ、５μＭまたは５０μＭそれぞれの濃度で処理して７２時間培養した。陽性対照群として、脱毛治療剤として使用されるミノキシジル（minoxidil）５μＭを処理した。その後、細胞増殖を測定するために、ＭＴＴ（3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide））法を遂行した。具体的には、３－（４，５－ジメチルチアゾール－２－イル）－２，５－ジフェニルテトラゾリウムプロミド（ＭＴＴ）４μｇ／ｍｌを処理し、４時間後、ＤＭＳＯを処理してポルマザンを溶解させ、それを、分光光度計を利用し、５６０ｎｍにおける吸光度を測定した。

Example 2: Confirmation of hair follicle cell proliferation or activation promoting effect of peptide 1. Confirmation of Effect of Promoting Proliferation of Dermal Papilla Cells The effect of promoting proliferation of hair follicle cells by the peptide consisting of the amino acid sequence of SEQ ID NO: 1 is confirmed. Specifically, human hair follicle dermal papilla cells were seeded in a 96-well plate at a density of 5×10 ³ cells/well and cultured for 16 hours. After changing to a serum-free medium, the peptides were treated at concentrations of 0.5 μM, 5 μM or 50 μM, respectively, and cultured for 72 hours. A positive control group was treated with 5 μM of minoxidil, which is used as a treatment for hair loss. After that, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)) method was performed to measure cell proliferation. Specifically, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was treated at 4 μg/ml, and after 4 hours, treated with DMSO to dissolve pormazan. The absorbance at 560 nm was measured using a spectrophotometer.

As a result, as shown in FIG. 1, it was confirmed that the peptide consisting of the amino acid sequence of SEQ ID NO: 1 promotes proliferation of human dermal papilla cells.

2. Confirmation of Activating Effect of Factors Related to Proliferation of Dermal Papilla Cells The activating effect of the peptide consisting of the amino acid sequence of SEQ ID NO: 1 on factors involved in proliferation of hair follicle cells is confirmed. Specifically, human hair follicle papilla cells were seeded in a 6-well plate at a density of 4×10 ⁵ cells/well and then cultured for 16 hours. After changing to serum-free medium, the peptides were treated at concentrations of 0.5 μM, 5 μM or 50 μM, respectively, and incubated for 30 minutes. As a positive control group, minoxidil 5 μM was treated. After harvesting cells and preparing cell lysates, Western blotting for phosphorylated ERK and phosphorylated AKT was proceeded using p-ERK and p-AKT antibodies (Santacruz Biotechnology, USA). .

As a result, as shown in FIG. 2, it was confirmed that treatment with a peptide consisting of the amino acid sequence of SEQ ID NO: 1 induces phosphorylation of ERK and AKT, which are factors involved in proliferation of dermal papilla cells. . Based on the above results, it can be confirmed that factors related to proliferation of dermal papilla cells are activated.

3. Confirmation of Effect of Promoting Proliferation Mechanism of Dermal Papilla Cells The effect of activating the proliferation mechanism of hair follicle cells by the peptide consisting of the amino acid sequence of SEQ ID NO: 1 is confirmed. Specifically, human hair follicle papilla cells were seeded in a 6-well plate at a density of 4×10 ⁵ cells/well and then cultured for 16 hours. After changing to a serum-free medium, the peptides were treated at concentrations of 0.5 μM, 5 μM or 50 μM, respectively, and cultured for 24 hours. As a positive control group, minoxidil 5 μM was treated. Cells were harvested and nuclear proteins were isolated using a nuclear protein extraction kit (Merck, USA). Using a β-catenin antibody (Santacruz Biotechnology, USA), Western blotting was carried out for β-catenin, a factor involved in proliferation of dermal papilla cells.

As a result, as shown in FIG. 3, it was confirmed that treatment with a peptide consisting of the amino acid sequence of SEQ ID NO: 1 increased the translocation of β-catenin from the cytoplasm to the nucleus. Based on the above results, it can be confirmed that β-catenin translocated to the nucleus is increased and acts as a transcription factor, thereby promoting the growth mechanism of dermal papilla cells.

Example 3: Confirmation of inhibitory effect of peptide on hair loss-related factor expression
1. Confirmation of DKK-1 expression inhibitory effect in dermal papilla cells A peptide consisting of the amino acid sequence of SEQ ID NO: 1 was placed in hair follicle cells to confirm whether or not the expression of DKK-1, a hair loss-related factor, was inhibited. do. Specifically, human hair follicle papilla cells were seeded in a 6-well plate at a density of 4×10 ⁵ cells/well and then cultured for 16 hours. After changing to a serum-free medium, the cells were treated with 10 μg/ml of dihydrotestosterone (DHT) as a stimulator and 0.5 μM, 5 μM or 50 μM of the peptide, and cultured for 24 hours. Cells were harvested and nuclear protein was isolated using a nuclear protein extraction kit. A DKK-1 antibody (Santacruz Biotechnology, USA) was utilized to proceed with Western blotting against DKK-1. DHT is known to be a hair loss hormone that activates androgen receptors and increases the expression of DKK-1 (Dickkopf-related protein 1), a factor that induces hair loss.
As a result, as shown in FIG. 4, it was confirmed that the peptide consisting of the amino acid sequence of SEQ ID NO: 1 can suppress the expression of DKK-1, which is a hair loss-inducing factor induced by DHT treatment.

2. Confirmation of Effect of Suppressing TGFβ-1 Expression in Dermal Papilla Cells It is confirmed whether the peptide consisting of the amino acid sequence of SEQ ID NO: 1 suppresses the expression of TGFβ-1, a hair loss-related factor, in hair follicle cells. Specifically, human hair follicle papilla cells were seeded in a 6-well plate at a density of 4×10 ⁵ cells/well and then cultured for 16 hours. After changing to a serum-free medium, the peptides were treated at concentrations of 0.5 μM, 5 μM or 50 μM, respectively, and cultured for 24 hours. As a positive control group, minoxidil 5 μM was treated. After cell harvesting and RNA isolation, cDNA was synthesized using a cDNA synthesis kit and PCR pre-mix, and PCR (polymerase chain reaction) was performed using TGFβ-1 primers and GAPDH primers listed in Table 2 below. . Said TGFβ-1 is an androgen-inducible factor in hair follicle cells and is known to be associated with hair loss.

As a result, as shown in FIG. 5, the peptide consisting of the amino acid sequence of SEQ ID NO: 1 was able to suppress the expression of TGFβ-1, which is known as a hair loss-inducing factor, in hair follicle cells. confirmed.

The foregoing description of the invention is for illustrative purposes only, and a person skilled in the art to which this invention pertains may make other specific modifications without changing the spirit or essential characteristics of the invention. It will be understood that it can be easily transformed into various forms. Accordingly, the embodiments described above are to be considered in all respects as illustrative and not restrictive.

Claims (6)

A peptide consisting of the amino acid sequence of SEQ ID NO:1. The N-terminus of the peptide is acetyl, fluorenylmethoxycarbonyl, formyl, palmitoyl, myristyl, stearyl, butoxycarbonyl (Boc), allyloxycarbonyl (Alloc) and polyethylene glycol (PEG). 2. The peptide according to claim 1, which is bound with any one protecting group selected from the group consisting of wherein the C-terminus of said peptide is bound with any one protecting group selected from the group consisting of amino group (-NH ₂ ), tertiary alkyl group and azide (-NHNH ₂ ); Item 1. The peptide according to item 1. 2. The peptide of claim 1, wherein said peptide exhibits any one or more properties selected from:
(a) promoting the activity of hair follicle cells;
(b) promotion of hair follicle cell proliferation;
(c) inhibition of hair follicle cell death, and (d) inhibition of DKK-1 (Dickkopf-related protein 1) or TGF-β1 (transforming growth factor-beta 1) expression. A cosmetic composition for improving hair loss or promoting hair growth, comprising the peptide according to any one of claims 1 to 4 as an active ingredient. A pharmaceutical composition for preventing or treating hair loss, comprising the peptide according to any one of claims 1 to 4 as an active ingredient.

Images